GC BioPharma Received WHO Pre-Qualification for Filling and Finish Plant in Ochang
GC BioPharma Exceeded 300 million doses of flu vaccine production
GC BioPharma Received WHO Pre-Qualification for BARYCELA
GC BioPharma Established Corporate Compliance Management System
GC Genome awarded Good Clinical Laboratory Practice(GCLP) status
GC - GC Cell acquires BioCentriq in US
GC Wellbeing completes contruction on innovation plant in Eumseong, Chungbuk
GC LabCell / GC Cell merges together under integrated company GC Cell
GC LabCell joins hands with Artiva MSD to export X trillion-sized CAR-NK technology
GC BioPharma obtains product license
for the world’s first severe Hunter syndrome treatment [Hunterase ICV] in Japan,
and for a recombinant treatment for hemophilia [Greengene F] in China
Established GreenVet
GC Labs designated as the first in vitro
diagnostic medical device clinical performance testing institution in Korea
GC BioPharma obtains product license for [Barycela],
a next generation varicella vaccine
GC BioPharma obtains first product license in China for [Hunterase]
to treat Hunter Syndrome
GC Biopharma exceeded 200 million doses of flu vaccine production
GC Wellbeing successfully completes IPO
Establishment of GCCL
GC BioPharma receives <200 Million USD Export Tower> Award
GC Cell completes Cell Center
Establishement of Curevo
GC Genome acquires CAP certification
GC BioPharma's GCFLU Quadrivalent becomes second in the world
to pass WHO prequalification
GC BioPharma obtains product license of [GC TD Vaccine],
Korea’s first DPT (Diphtheria, Pertussis, and Tetanus) vaccine
GC Cell successfully completes IPO
GC MS acquires CeragemMedisys (GC Medis) and begins operations on diabetes business
GC Labs awarded <2015 Korea ICT Innovation> Grand Prize by Minister of Science, ICT and Future Planning
GC BioPharma becomes fourth company in the world to obtain product license for quadrivalent seasonal flu vaccine [GCFLU Quadrivalent]
GC BioPharma becomes first company in Korea to obtain product license for H5N1 (avian flu) vaccine [GCFLU H5N1]
GC MS successfully completes IPO
GC MS becomes first company in the world to obtain product license
for multiple diagnosis influenza diagnostic kit
GC BioPharma surpasses over over 100 million doses of GCFLU production
GC BioPharma receives <100 Million USD Export Tower> Award
Established GC Genome
GC MS merges with Gambro Korea Solution, begins hemodialysis business
GC BioPharma begins construction on blood plasma fractionation plant in Thailand (with Thai Red Cross)
Completion of GC R&D Center, the largest scale R&D center among pharmaceutical industry in Korea
GC BioPharma becomes second company in the world to obtain product license for Hunter syndrome treatment [Hunterase]
GC Cell established as a result of acquiring Innocell
Established GC LabCell
GC BioPharma obtaines product license for natural medicine osteoarthritis treatment [Sinbaro]
GC BioPharma completes construction of Korea's first vaccine-exclusive Hwasun plant
GC BioPharma obtaines product license for H1N1 influenza vaccine [GREEN FLU] and Korea’s first trivalent flu vaccine [GCFLU]
GC BioPharma completes construction of Ochang plant, a state-of-the-art blood product and gene recombination production facility
GC BioPharma becomes fourth company in the world to obtain product license for recombinant hemophilia-A treatment (GreenGene)
Established GC Invacfarm
GC MS acquires product license for magnetic diagnostic reagent for the first time in Korea
GC Wellbeing obtaines product license for placenta injection [Laennec]
Established GC Wellbeing
Established GSMS
GC BioPharma acquires Sang-A Pharmaceuticals
Completes construction of Jeongseong Green Cross Pharmaceutical Center and plant
Established GC China, Anhui Green Cross Bio Products Limited in China Completion of vaccine plant in Indonesia
Becomes second company in the world to obtain product license for varicella vaccine [Suduvax]
Launched Green Friends Association
Mogam Science Scholarship Foundation achieves product license for AIDS diagnostic reagent
GC BioPharma successfully completes IPO
Becomes first pharmaceutical company in the world to obtain product license for vaccine against hemorrhagic fever with renal syndrome [Hantavax]
Becomes third pharmaceutical company in the world to obtain product license for hepatitis-B vaccine [Hepavax-B]
Established GC Labs, obtains product license for IVIG [I.V.-Globulin]
Obtains product license for anti-hemophilic factor [AHF]
Obtains product license for Korea’s first stroke treatment [Urokinase]
Name change to Green Cross BioPharma Incorporated Completion of first blood plasma fractionation plant
Completion of Singal plant
Established as Sudo Microorganism Medical Supplies Company